SCHEMBL5397257

SCHEMBL5397257

O=C(O)NCCc1cccc(-c2ccc(C=C3SC(=O)NC3=O)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 4/20 0.52
HPGD P15428 10/20 0.51
MEN1 O00255 1/20 0.50
POLB P06746 1/20 0.50
KMT2A Q03164 1/20 0.50
MAOA P21397 1/20 0.49
MAOB P27338 1/20 0.49
PIM1 P11309 2/20 0.48
PIM2 Q9P1W9 2/20 0.48
PIM3 Q86V86 1/20 0.48
AKR1B1 P15121 1/20 0.47
NAT1 P18440 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5386765 0.89 MAOA (0.54) PTPN1HPGDMEN1POLBKMT2A
SCHEMBL5386774 0.89 MAOA (0.54) PTPN1HPGDMEN1POLBKMT2A
SCHEMBL1751361 0.85 PRF1 (0.50) PTPN1HPGDMAOAMAOB
SCHEMBL6184231 0.81 MAOA (0.53) PTPN1HPGDMEN1POLBKMT2A
SCHEMBL6184236 0.81 MAOA (0.53) PTPN1HPGDMEN1POLBKMT2A
SCHEMBL6204803 0.80 MAOA (0.55) PTPN1HPGDMEN1POLBKMT2A
SCHEMBL6473102 0.80 PTPN1 (0.49) PTPN1HPGDMEN1POLBKMT2A
SCHEMBL6204806 0.80 MAOA (0.55) PTPN1HPGDMEN1POLBKMT2A
SCHEMBL6183335 0.79 MAOA (0.56) PTPN1HPGDMEN1POLBKMT2A
SCHEMBL6183331 0.79 MAOA (0.56) PTPN1HPGDMEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7294639-B2 Biaromatic ligand activators of PPARγ receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-11-13 US disclosed
US-20070043046-A1 Biaromatic ligand activators of PPARGAMMA receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2007-02-22 US disclosed
US-7122564-B2 Biaromatic ligand activators of PPARγ receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2006-10-17 US disclosed
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US disclosed
US-20050137238-A1 Biaromatic ligand activators of PPARgamma receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. 2005-06-23 US disclosed
US-6908939-B2 Biaromatic ligand activators of PPARγ receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2005-06-21 US disclosed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US disclosed
US-20030134885-A1 Biaromatic ligand activators of PPARgamma receptors GALDERMA RESEARCH & DEVELOPMENT (FR) 2003-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043046-A1 Biaromatic ligand activators of PPARGAMMA receptors PPARG, PPARA, PPARD PTPN1 2623/4885HPGD 512/4885MEN1 4881/4885
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors PPARG, PPARA, PPARD PTPN1 1579/4885HPGD 492/4885MEN1 4750/4885
US-20050137238-A1 Biaromatic ligand activators of PPARgamma receptors PPARG, PPARA, PPARD PTPN1 2623/4885HPGD 512/4885MEN1 4881/4885
US-20030134885-A1 Biaromatic ligand activators of PPARgamma receptors PPARG, PPARA, PPARD PTPN1 2343/4885HPGD 557/4885MEN1 4878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.